ライフサイエンスコーパス: balloon-expandable

1 theter valve type (balloon-expandable or non-balloon-expandable).

2 Overall 898 chimney grafts (49.2% balloon expandable, 39.6% self-expanding covered stents,

3 31 consecutive patients undergoing TAVR with balloon-expandable (58%) or self-expandable (42%) valves

4 anscatheter aortic valve implantation with a balloon-expandable (64%) or self-expandable (36%) valve.

5 4 mm in diameter were treated with the new, balloon-expandable ACS MultiLink stent.

6 aim to compare the safety and performance of balloon-expandable and self-expandable transcatheter hea

7 tive patients underwent MDCT pre-TAVR with a balloon expandable aortic valve.

8 Use of balloon-expandable aortic transcatheter heart valves in

9 ViR), and mitral valve-in-valve (MViV) using balloon-expandable aortic transcatheter heart valves.

10 ranscatheter mitral valve replacement with a balloon-expandable aortic valve platform.

11 .6% self-expanding covered stents, and 11.2% balloon expandable bare metal stents) were placed in 692

12 Between 1990 and 2004, deployment of balloon-expandable bare stents was attempted in 242 obst

13 No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transca

14 and the predictors of such a complication in balloon-expandable (BE) and self-expandable (SE) TAVR re

15 r the initial learning curve (LC), a VOR for balloon-expandable (BE) TAVR persisted; and 2) to determ

16 e the outcomes of TAVR according to Sapien 3 balloon-expandable (BE) versus Evolut R self-expanding T

17 d 1521 underwent TF-TAVR with Edwards SAPIEN balloon-expandable bioprostheses.

18 ortic stenosis to either SAVR or TAVR with a balloon-expandable bovine pericardial tissue valve by ei

19 ranscatheter aortic-valve replacement with a balloon-expandable bovine pericardial valve (either a tr

20 transfemoral transcatheter implantation of a balloon-expandable bovine pericardial valve.

21 Balloon, expandable, cobalt-chrome covered stent (Jotec,

22 The balloon-expandable coil stent has been proved effective

23 Patients who receive the coronary balloon-expandable coil stent with optimal angiographic

24 ber 1994 and May 1995, 369 patients received balloon-expandable coil stents in native coronary arteri

25 the use of local anesthesia, implantation of balloon expandable device, avoidance of urinary catheter

26 nvestigated the efficacy and safety of using balloon expandable drug-eluting stents (DES) to prevent

27 oston Scientific Lotus valve (Lotus) and the balloon-expandable Edwards Sapien 3 (ES3) valve.

28 ore: 9.8 +/- 6.4%) who underwent TAVI with a balloon-expandable Edwards valve (transfemoral: 48%, tra

29 30-day clinical outcomes (Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable Cor

30 lly available valve (either an intra-annular balloon-expandable Edwards-SAPIEN, SAPIEN XT, or SAPIEN

31 e the development of balloon angioplasty and balloon-expandable endovascular stent technology in the

32 Restenosis within balloon-expandable endovascular stents may occur as a re

33 Balloon-expandable endovascular stents provide a luminal

34 The balloon-expandable ES prosthesis caused significantly mo

35 emoral and the transapical approach with the balloon-expandable ES stent valve, transfemoral TAVI wit

36 follow-up were observed in 4 patients in the balloon-expandable group (3.4% vs. 0%; p = 0.12); all we

37 ed by percutaneous delivery of a 15-mm-long, balloon-expandable metallic stent was performed in 64 ra

38 Precise sizing of the balloon-expandable Myval transcatheter heart valve (THV)

39 atients who underwent TAVI with the use of a balloon-expandable (n=22) or self-expandable (n=10) sten

40 rmed in 20 patients undergoing VIV TAVR with balloon-expandable (n=8) or self-expanding (n=12) transc

41 TAVR), or by index transcatheter valve type (balloon-expandable or non-balloon-expandable).

42 Transfemoral TAVR with a balloon-expandable or self-expandable device.

43 heter deployment of valves requires either a balloon-expandable or self-expandable system.

44 al valves to facilitate VIV TAVR with either balloon-expandable or self-expanding transcatheter valve

45 The TAVI procedure can be performed using a balloon-expandable or self-expanding valve.

46 y assigned 1:1 to either SAVR or TAVR with a balloon expandable pericardial tissue valve.

47 risk of aortic root rupture during TAVR with balloon-expandable prostheses.

48 358 patients underwent transapical TAVI with balloon-expandable prostheses.

49 ocedural strategy of transapical TAVI with a balloon-expandable prosthesis was associated with a low

50 Our novel technique for balloon-expandable S3 valve positioning consistently ach

51 id not meet noninferiority compared with the balloon-expandable SAPIEN 3 (S3) device regarding a comp

52 did not meet non-inferiority compared to the balloon-expandable SAPIEN 3 device in terms of early saf

53 f-expanding ACURATE neo TAVR system with the balloon-expandable SAPIEN 3 TAVR system with regard to e

54 The new balloon-expandable Sapien 3 transcatheter heart valve (S

55 me) European registry for treatment with the balloon-expandable SAPIEN 3 transcatheter heart valve an

56 ted with the self-expanding NEO2 (n=1457) or balloon-expandable SAPIEN 3 Ultra (n=530) from January 2

57 heter self-expanding ACURATE neo2 (NEO2) and balloon-expandable SAPIEN 3 Ultra prostheses in technica

58 to undergo either transfemoral TAVR with the balloon-expandable SAPIEN 3 valve or SAVR.

59 The conventional method of implanting balloon-expandable SAPIEN-3 (S3) valve results in a fina

60 how noninferiority to commercially available balloon-expandable (SAPIEN 3/3 Ultra) and self-expanding

61 mography screening for HALT at 30 days after balloon-expandable SAPIEN3 and self-expanding EVOLUT TAV

62 dy investigated the efficacy and safety of a balloon expandable, sirolimus-eluting stent (SES) in pat

63 The Multi-Link stent is a balloon-expandable stainless steel stent with an interco

64 ocalized drug delivery was accomplished with balloon-expandable stainless steel stents coated with a

65 The balloon-expandable, stainless steel, hourglass-shaped, c

66 ation], SIRIUS [SIRolImUS-coated Bx Velocity balloon expandable stent in the treatment of patients wi

67 raphy) from the Sirolimus-coated Bx Velocity Balloon Expandable Stent in the Treatment of Patients wi

68 were performed in 55 lesions treated with a balloon-expandable stent (ACS MultiLink) using standard

69 ry stenoses, who underwent implantation of a balloon-expandable stent after unsuccessful percutaneous

70 ng stent group (n = 32) or the Palmaz-Schatz balloon-expandable stent group (n = 30).

71 Balloon-expandable stent implantation in the SVGs of hig

72 particular, the implications of deploying a balloon-expandable stent in a compressible site are not

73 nd vascular response to placement of a novel balloon-expandable stent in swine with experimentally in

74 The SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients wi

75 81420; Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native

76 ypotension developed in 33.9% of cases after balloon-expandable stent placement versus in 13.6% of ca

77 efit of heparin coating with the BX VELOCITY Balloon-Expandable Stent with HEPACOAT, Carmeda end-poin

78 TIPS (eight with flexible PTFE-encapsulated balloon-expandable stent-grafts and four control TIPS wi

79 tion of stents in the treatment of IAs, from balloon expandable stents, to self-expanding stents, to

80 Balloon-expandable stents (8 types) were used in the maj

81 Short balloon-expandable stents (mean diameter, 14.6 mm +/- 1.

82 Balloon-expandable stents anchored the ends of the graft

83 Balloon-expandable stents are being used increasingly in

84 Balloon-expandable stents covered with polytetrafluoroet

85 Balloon-expandable stents have been used in pulmonary ar

86 Endovascular treatment with balloon-expandable stents is effective, safe, and appare

87 l, Palmaz (Cordis Corp., Warren, New Jersey) balloon-expandable stents provide a safe and durable rev

88 Balloon-expandable stents were placed in 100 consecutive

89 have significant implications for the use of balloon-expandable stents within vascular sites subject

90 leading to larger follow-up lumens than with balloon-expandable stents.

91 sinus stimulation is frequent after CAS with balloon-expandable stents.

92 th patients were treated percutaneously with balloon-expandable stents.

93 SFAs) and hemodialysis conduits treated with balloon-expandable stents.

94 (TAVR) have been based primarily on a single balloon-expandable system.

95 Contained rupture of the aortic root in balloon-expandable TAVI is associated with severe prosth

96 rtic valve area 0.69+/-0.19 cm(2)) underwent balloon-expandable TAVI using the EdwardsSAPIEN Transcat

97 and the frequency of this complication after balloon-expandable TAVI.

98 evaluate the safety and efficacy of PD after balloon expandable TAVR.

99 ify predictors of aortic root rupture during balloon-expandable TAVR by using multidetector computed

100 omatic aortic stenosis and were treated with balloon-expandable TAVR in a single center.

101 in patients with greater than mild PVR after balloon-expandable TAVR.

102 atheter heart valve type (self-expanding vs. balloon-expandable) that fits the given anatomy best.

103 Intentionally underexpanding balloon-expandable THV by underfilling the deployment ba

104 lve implantation using the newest generation balloon-expandable THV is associated with a low risk of

105 The use of the new generation S3 balloon-expandable THV reduced the risk of more than mil

106 Recommendations for balloon-expandable THV size selection were based on an M

107 n MSCT-based TAV sizing was performed (16.7% balloon-expandable THV vs. 17.6% self-expandable THV, p

108 on (AR) grade >/= 2 occurred in 28.4% (19.6% balloon-expandable THV vs. 32.2% self-expandable THV, p

109 sizing was used in 63.5% of patients (77.1% balloon-expandable THV vs. 56.0% self-expandable THV, p

110 c valve replacement (TAVR) with contemporary balloon expandable transcatheter valves in patients with

111 11 and December 2014, 167 patients underwent balloon-expandable transcatheter aortic valve implantati

112 e of contained rupture of the aortic root in balloon-expandable transcatheter aortic valve implantati

113 pansion and guide further optimization after balloon-expandable transcatheter aortic valve replacemen

114 DCT and 3D-TEE for annulus assessment before balloon-expandable transcatheter aortic valve replacemen

115 Aortic root rupture is a major concern with balloon-expandable transcatheter aortic valve replacemen

116 eart valve (Symetis ACURATE neo, n=129) or a balloon-expandable transcatheter heart valve (Edwards SA

117 A balloon-expandable transcatheter heart valve (SAPIEN 3,

118 f 139 patients underwent TAV-in-BAV with the balloon-expandable transcatheter heart valve (THV) (n =

119 hy scans of bicuspid patients who received a balloon-expandable transcatheter heart valve (THV) in th

120 In the LANDMARK trial, the Myval balloon-expandable transcatheter heart valve (THV) serie

121 The use of a balloon-expandable transcatheter heart valve previously

122 s observed in 14% of subjects who received a balloon-expandable transcatheter heart valve.

123 which encircles the chordae tendineae, and a balloon-expandable transcatheter heart valve.

124 f PVR following TAVR with a third-generation balloon-expandable transcatheter heart valve.

125 associated with a strategy of underexpanding balloon-expandable transcatheter heart valves (THV) when

126 nce of new-generation self-expandable versus balloon-expandable transcatheter heart valves in bicuspi

127 MViV using aortic balloon-expandable transcatheter heart valves is associa

128 rmine the midterm hemodynamic performance of balloon-expandable transcatheter heart valves.

129 r postprocedural gradients in both self- and balloon-expandable transcatheter valves.

130 cemaker following TAVR, and 88.5% received a balloon expandable valve.

131 compare the hemodynamic results between the balloon-expandable valve (BEV) SAPIEN (3/ULTRA, Edwards

132 s of patients with IE post-TAVR treated with balloon-expandable valve (BEV) versus self-expanding val

133 the self-expanding valve and 10.6% with the balloon-expandable valve (difference, -1.2 percentage po

134 the self-expanding valve and 41.6% with the balloon-expandable valve (difference, -32.2 percentage p

135 patients were randomly assigned to receive a balloon-expandable valve (Edwards Sapien XT) and 120 wer

136 rtery bypass graft (p = 0.043), the use of a balloon-expandable valve (p = 0.023), and previous surgi

137 transient or absent) LBBB after TAVI with a balloon-expandable valve and its clinical consequences a

138 permanent pacemaker was less frequent in the balloon-expandable valve group (17.3% vs 37.6%, P = .001

139 anding valve group and 35.3% of those in the balloon-expandable valve group (P<0.001).

140 end point occurred in 18.2% of those in the balloon-expandable valve group and 23.1% of the self-exp

141 ascular mortality at 30 days was 4.1% in the balloon-expandable valve group and 4.3% in the self-expa

142 curred in 116 of 121 patients (95.9%) in the balloon-expandable valve group and 93 of 120 patients (7

143 than 1 valve (0.8% vs 5.8%, P = .03) in the balloon-expandable valve group.

144 tched cohort, although patients treated with balloon-expandable valve had a higher rate of annular ru

145 d with SAVR, the second-generation SAPIEN XT balloon-expandable valve has a higher 5-year rate of SVD

146 onary accessibility after simulated Sapien-3 balloon-expandable valve implantation within an Evolut s

147 needed at 3-year follow-up after TAVI with a balloon-expandable valve in 3.5% of patients and was suc

148 early TAVR with transfemoral placement of a balloon-expandable valve or clinical surveillance.

149 were randomized to transfemoral TAVR using a balloon-expandable valve or surgery in the PARTNER 3 (Pl

150 either TAVR with transfemoral placement of a balloon-expandable valve or surgery.

151 e randomized 1:1 to transfemoral TAVI with a balloon-expandable valve or surgery.

152 ortic stenosis undergoing TAVR, the use of a balloon-expandable valve resulted in a greater rate of d

153 eplacement (TAVR) with an earlier generation balloon-expandable valve to be noninferior to surgical a

154 Mitral valve-in-valve with a balloon-expandable valve via transseptal approach in int

155 A balloon-expandable valve was used in 83.7% of cases.

156 ar outcomes following successful TAVI with a balloon-expandable valve were evaluated in 88 patients.

157 implantation (PPI) who underwent TAVI with a balloon-expandable valve were included.

158 Transseptal access and the balloon-expandable valve were used in 33.1% and 89.9%, r

159 ding supraannular valve was noninferior to a balloon-expandable valve with respect to clinical outcom

160 pite the higher device success rate with the balloon-expandable valve, 1-year follow-up of patients i

161 ces developed new LBBB following TAVI with a balloon-expandable valve, although it was transient in m

162 frequently in women, in patients receiving a balloon-expandable valve, and in those with a previous s

163 self-expanding valve and 15.7 mm Hg with the balloon-expandable valve, and the corresponding values f

164 y score adjustment for covariates (age, sex, balloon-expandable valve, annulus diameter, and valve ov

165 o were suitable for transfemoral TAVR with a balloon-expandable valve.

166 her a self-expanding supraannular valve or a balloon-expandable valve.

167 self-expandable valve and 80 (34.7%) with a balloon-expandable valve.

168 rial fibrillation (AF) underwent TAVI with a balloon-expandable valve.

169 eter aortic valve implantation (TAVI) with a balloon-expandable valve.

170 TVIV was accomplished in all patients using balloon expandable valves (Edwards Lifesciences, Irvine,

171 r-generation self-expanding valves (SEV) and balloon-expandable valves (BEV) as well as local anesthe

172 r-generation self-expanding valves (SEV) and balloon-expandable valves (BEV), as well as conscious se

173 925 patients who underwent TAVR with current balloon-expandable valves (SAPIEN 3, SAPIEN 3 Ultra, or

174 of Second-Generation Self-Expandable Versus Balloon-Expandable Valves and General Versus Local Anest

175 Son of secOnd-generation seLf-expandable vs. balloon-expandable Valves and gEneral vs. local anesthes

176 Son of secOnd-generation seLf-expandable vs. balloon-expandable Valves and gEneral vs. local anesthes

177 ic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementatio

178 otal of 309 505 patients underwent TAVR with balloon-expandable valves during the study period.

179 Redo-TAVR with balloon-expandable valves effectively treated dysfunctio

180 Since the introduction of the first balloon-expandable valves for stenotic lesions with impl

181 xpandable valves are emerging complements to balloon-expandable valves for transcatheter pulmonary va

182 011, to Dec 30, 2022 who underwent TAVR with balloon-expandable valves in failed transcatheter heart

183 ransient arrhythmic adverse event rates than balloon-expandable valves in the early postoperative per

184 s and outcomes of self-expandable valves and balloon-expandable valves in transcatheter pulmonary val

185 Redo-TAVR with balloon-expandable valves might be a reasonable treatmen

186 alve replacement with Edwards SAPIEN 3 (ES3) balloon-expandable valves or Venus-P self-expandable val

187 rt-term prognosis, outcomes for contemporary balloon-expandable valves remain unknown.

188 TranscathetER aortic valve implantation with balloon-expandable valves versus self-expandable valves)

189 Acute outcomes after TPVR with balloon-expandable valves were generally excellent in al

190 Balloon-expandable valves were used in 97% of cases, wit

191 al aortic regurgitation moderate after TAVR, balloon-expandable valves, IE within 30 days after TAVR,

192 g patients undergoing contemporary TAVR with balloon-expandable valves.

193 potential impact of MS on TAVR outcomes with balloon-expandable valves.

194 Valve type (balloon-expandable vs. self-expandable, p = 0.26) and ap